Journals / MN Kardiyoloji / 2020 / Cilt: 27 - Sayı: 2

The Effects of Acetylsalicylic Acid Resistance on Cardiovascular Events in Patients Taking Acetylsalicylic Acid for Coronary Artery Disease

Koroner Arter Hastalığı Nedeni ile Asetilsalisilik Asit Kullanan Hastalarda Asetilsalisilik Asit Direncinin Kardiyovasküler Olay Üzerine Etkisi

Pages
85–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further prospective, randomized trials are needed in this group of patients to routinely assess acetylsalicylic acid resistance and to learn its true prevalence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Acetylsalicylic acid is a strong antiaggregant that is used to prevent atherothrombotic cardiovascular events.
📊
Key Findings & Data:Results: When the two groups were compared, it was noted that 12 (17.4%) of the 67 patients with hypertension had acetylsalicylic acid resistance, while only 1 (3.2%) of the 31 patients without hypertension had acetylsalicylic acid resistance.
💡
Conclusion & Impact:Further prospective, randomized trials are needed in this group of patients to routinely assess acetylsalicylic acid resistance and to learn its true prevalence.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Acetylsalicylic acid is a strong antiaggregant that is used to prevent atherothrombotic cardiovascular events. In the present study, we investigated the effects of acetylsalicylic acid resistance on secondary thromboembolic events in patients who regularly use acetylsalicylic acid for the treatment of coronary artery disease. Material and Method: The patients, who all use acetylsalicylic acid for the treatment of coronary artery disease, were divided into two groups based on the presence of a recurrent cardiovascular event and a measurement of acetylsalicylic acid resistance using a multiplate platelet function analyzer. We then made a comparison of the demographical and biochemical data of the two groups. Results: When the two groups were compared, it was noted that 12 (17.4%) of the 67 patients with hypertension had acetylsalicylic acid resistance, while only 1 (3.2%) of the 31 patients without hypertension had acetylsalicylic acid resistance. Acetylsalicylic acid resistance was statistically and significantly more frequent in hypertensive patients (p: 0.044), while no statistically significant difference was noted between the two groups in terms of the other demographical and biochemical parameters. Conclusion: Although acetylsalicylic acid resistance did not have any effect on the new cardiovascular event, we found that 13% of the patients had acetylsalicylic acid resistance. Therefore, the effectiveness of the treatment can be evaluated by looking at the resistance of acetylsalicylic acid in patients undergoing cardiovascular events under acetylsalicylic acid treatment. Further prospective, randomized trials are needed in this group of patients to routinely assess acetylsalicylic acid resistance and to learn its true prevalence.

Özet

Amaç: Asetilsalisilik asit, aterotrombotik kardiyovasküler olayların önlenmesinde kullanılan güçlü bir antiagregandır. Çalışmamızda koroner arter hastalığı nedeni ile düzenli asetilsalisilik asit kullanan hastalarda gelişen sekonder tromboembolik olaylarda asetilsalisilik asit rezistansının etkisini araştırdık. Gereç ve Yöntem: Koroner arter hastalığı nedeni ile asetilsalisilik asit kullanan hastaları, yeni kardiyovasküler olay geçiren ve geçirmeyenler olarak 2 gruba ayırdık ve asetilsalisilik asit rezistansını platelet fonksiyon analizatörü ile ölçtük. Gruplar arasındaki demografik ve biyokimyasal özellikleri kıyasladık. Bulgular: İki grup arasında hipertansiyonu olan 67 hastanın 12’sinde (%17,4) asetilsalisilik asit direnci var iken hipertansiyonu olmayan 31 hastanın sadece 1’ inde (%3,2) asetilsalisilik asit direnci saptandı. Hipertansif hastalarda asetilsalisilik asit direnci istatiksel olarak anlamlı bulundu (p: 0,044) diğer demografik ve biyokimyasal parametreler arasında istatiksel fark saptanmadı. Sonuç: Koroner arter hastalığı saptanan ve düzenli olarak asetilsalisilik asit kullanan olgularda asetilsalisilik asit direnci yeni kardiyovasküler olaya etkisi görülmemekle beraber, %13 hastada asetilsalisilik asit rezistansı olduğunu saptadık. Bu nedenle asetilsalisilik asit tedavisi altında tekrar kardiyovasküler olay geçiren hastalarda asetilsalisilik asit direnci bakılarak tedavinin etkinliği değerlendirilebilir. Ase til salisilik asit direncine rutin bakılabilmesi ve gerçek prevalansını öğrenebilmek için bu grup hastalarda daha fazla prospektif, randomize çalışmalara ihtiyaç vardır.

🔖

Cite This Article

AKIN, H., ALTINTAŞ, B., BİLGE, Ö. (2020). The Effects of Acetylsalicylic Acid Resistance on Cardiovascular Events in Patients Taking Acetylsalicylic Acid for Coronary Artery Disease. MN Kardiyoloji, Cilt: 27 - Sayı: 2, 85–90. https://ajindex.com/articles/297326

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bhatt DL. Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 2000;84:163-79
  2. Tekkeşin N. Ardal H. Tetik Ş. Kararlı Koro ner Arter Hastalığı Olanlarda Aspirin Direnci Sıklığı, Klinik ve Laboratuvar Bulgularla İlişkisi. T Klin J Med Sci. 2014;34(4):363-72
  3. Somuncu MU. Demir AR. Akurt H. et al. The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. Clin Appl Thromb Hemost. 2018; 24(8):1358-64
  4. Yassin AS. Abubakar H. Mishra T. et al. Aspirin Resistance: Cardiovascular Risk Game Changer. Am J Ther. 2019;26(5): 593-9
  5. Yılmaz MB. Balbay Y. Korkmaz Ş. Aspirin Direnci. Anadol Kardiyol. 2004;4:59-62
  6. Chadha DS. Sumana B. Karthikeyan G. Jayaprasad V. Arun SS. Prevalence of aspirin resistance in Asian-Indian patients with stable coronary artery disease. Cathet Cardiovasc Interv. 2016;88(4):E126-31
  7. Urbanowicz T. Komosa A. Michalak M. et al. The incidence of aspirin resistance in heart transplantation recipients. Kardiochir Torakochirurgia Pol. 2017;14(2):115-9
  8. Eikelboom JW. Hirsh J. Weitz JI. Johnston M. Yi Q. Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-5
  9. Hobikoğlu G, Norgaz T, Aksu H. ve ark. Aspirin Tedavisi Altında Akut Koroner Sendrom Gelişmesinde Aspirin Direncinin Rolü”, XIX. Ulusal Kardiyoloji Kongresi, Özet kitabı, özet SB02, Antalya, 2003. (Sözlü bildiri)
  10. Gum PA. Kottke-Marchant K. Welsh PA. White J. Topol EJ. A Prospective, blinded determination of the natural history of ASAresistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-5
  11. Pershukov IV. Ostaschenko SL. Kuznetsova TN. et al. Ability to Overcome the Thrombocyte Resistance to Acetylsa licy - lic Acid in Patients With Coronary Artery Disease After Myocardial Revascularization With Coronary Stenting. Kardiologiia. 2016;56(7):5-9
  12. Weber AA. Przytulski B. Schanz A. et al. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002;13:37-40
  13. Snoep JD. Hovens MC. Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med. 2007; 167(15):1593-159 14. Görlinger K. Jambor C. Hanke AA. et al. Periope